{"id":"NCT03868059","sponsor":"Lipocine Inc.","briefTitle":"Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal Men","officialTitle":"Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal Men","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-04-30","primaryCompletion":"2019-02-19","completion":"2019-02-21","firstPosted":"2019-03-08","resultsPosted":"2021-06-10","lastUpdate":"2021-06-10"},"enrollment":138,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hypogonadism, Male"],"interventions":[{"type":"DRUG","name":"LPCN 1021","otherNames":["TLANDO"]}],"arms":[{"label":"LPCN 1021","type":"EXPERIMENTAL"}],"summary":"This is an open-label, multi-center, single arm study evaluating the blood pressure (BP) changes from baseline (Visit 3) to post-treatment (Visit 5) assessed by ambulatory blood pressure monitoring (ABPM) in LPCN 1021 treated adult hypogonadal male subjects.","primaryOutcome":{"measure":"Change in Ambulatory Blood Pressure Monitoring (ABPM)-Measured Average 24-hour Systolic Blood Pressure (SBP)","timeFrame":"Baseline to end of study (approximately 4 months).","effectByArm":[{"arm":"LPCN 1021","deltaMin":3.8,"sd":11.8}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":16,"countries":["United States"]},"refs":{"pmids":["34191621"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":138},"commonTop":["Hypertension","Upper Respiratory Tract Infection","Haematocrit increased","Polycythemia","Gynaecomastia"]}}